FY2029 Earnings Forecast for RAPT Issued By Leerink Partnrs

RAPT Therapeutics, Inc. (NASDAQ:RAPT) – Stock analysts at Leerink Partnrs issued their FY2029 earnings per share (EPS) estimates for shares of RAPT Therapeutics in a note issued to investors on Wednesday, February 5th. Leerink Partnrs analyst T. Smith forecasts that the company will post earnings per share of ($0.30) for the year. The consensus estimate for RAPT Therapeutics’ current full-year earnings is ($2.43) per share.

Several other equities research analysts have also weighed in on the company. Wells Fargo & Company dropped their target price on RAPT Therapeutics from $17.00 to $4.00 and set an “overweight” rating on the stock in a research report on Tuesday, November 12th. Piper Sandler lowered shares of RAPT Therapeutics from an “overweight” rating to a “neutral” rating and reduced their target price for the company from $8.00 to $2.00 in a research note on Monday, November 11th. Stifel Nicolaus restated a “hold” rating and issued a $2.00 price target (down previously from $7.00) on shares of RAPT Therapeutics in a research note on Wednesday, November 13th. JPMorgan Chase & Co. downgraded RAPT Therapeutics from a “neutral” rating to an “underweight” rating in a research report on Monday, November 11th. Finally, HC Wainwright upgraded RAPT Therapeutics from a “neutral” rating to a “buy” rating and set a $10.00 target price on the stock in a research report on Thursday, December 26th. One analyst has rated the stock with a sell rating, nine have assigned a hold rating and three have given a buy rating to the company’s stock. According to MarketBeat, the stock currently has an average rating of “Hold” and an average target price of $9.56.

RAPT Therapeutics Trading Down 2.5 %

RAPT opened at $1.18 on Friday. RAPT Therapeutics has a fifty-two week low of $0.79 and a fifty-two week high of $27.35. The company’s 50-day moving average price is $1.26 and its 200 day moving average price is $1.79.

RAPT Therapeutics (NASDAQ:RAPT) last released its quarterly earnings data on Tuesday, November 12th. The company reported ($0.47) EPS for the quarter, topping analysts’ consensus estimates of ($0.56) by $0.09.

Institutional Inflows and Outflows

Large investors have recently bought and sold shares of the company. Barclays PLC raised its position in RAPT Therapeutics by 277.2% in the third quarter. Barclays PLC now owns 39,729 shares of the company’s stock worth $79,000 after acquiring an additional 29,195 shares in the last quarter. Renaissance Technologies LLC lifted its stake in RAPT Therapeutics by 108.1% during the second quarter. Renaissance Technologies LLC now owns 203,900 shares of the company’s stock valued at $622,000 after purchasing an additional 105,900 shares during the last quarter. Los Angeles Capital Management LLC boosted its holdings in RAPT Therapeutics by 138.1% during the third quarter. Los Angeles Capital Management LLC now owns 201,439 shares of the company’s stock worth $405,000 after buying an additional 116,853 shares in the last quarter. AQR Capital Management LLC acquired a new position in RAPT Therapeutics in the second quarter worth approximately $270,000. Finally, Exchange Traded Concepts LLC grew its position in RAPT Therapeutics by 244.7% in the third quarter. Exchange Traded Concepts LLC now owns 89,076 shares of the company’s stock worth $179,000 after buying an additional 63,235 shares during the last quarter. Institutional investors own 99.09% of the company’s stock.

About RAPT Therapeutics

RAPT Therapeutics, Inc, a clinical-stage immunology-based biopharmaceutical company, focuses on discovery, development, and commercialization of oral small molecule therapies for patients with unmet needs in oncology and inflammatory diseases in the United States. The company's lead inflammation drug candidate is zelnecirnon (RPT193), a C-C motif chemokine receptor 4 (CCR4) antagonist that selectively inhibit the migration of type 2 T helper cells into inflamed tissues.